Study on exosomes for identifying bipolar disorder in early stage: A cross-sectional and validation study protocol
Yanqing Wu1, Yuchao Li1, Xuguang An1
1Tianjin Mental Health Center, Tianjin Anding Hospital, Tianjin, China.
Brain and Behavior
|April 20, 2024
Summary
Plasma exosomes show promise as biomarkers for distinguishing early-stage bipolar disorder (BD) from major depressive disorder (MDD). This could lead to earlier diagnosis and improved treatment for BD patients, avoiding misdiagnosis and ineffective antidepressant use.
Area of Science:
- Neuroscience
- Biomarker Discovery
- Mental Health Diagnostics
Background:
- Accurate early-stage differentiation between bipolar disorder (BD) and major depressive disorder (MDD) remains challenging, leading to diagnostic delays of 5-10 years.
- Misdiagnosis of BD as MDD often results in inappropriate antidepressant treatment, negatively impacting disease progression and patient outcomes.
- Plasma exosomes offer a potential avenue for identifying reliable biomarkers for early BD detection.
Purpose of the Study:
- To investigate the utility of plasma exosome-derived microRNAs and proteins as biomarkers for differentiating early-stage bipolar disorder (BD) from major depressive disorder (MDD).
- To establish a diagnostic method for BD that can be applied in the early stages of the illness.
Main Methods:
- A two-stage study involving cross-sectional analysis of plasma exosome microRNA and protein concentrations in BD, MDD, and healthy control groups (n=40 each).
- Utilized Latent Class Analysis and Receiver Operating Characteristic analysis to identify and optimize potential biomarkers.
- Validation of identified biomarkers in individuals experiencing their first depressive episode, comparing biomarker-based diagnosis with DSM-5 criteria.
Main Results:
- Preliminary identification of specific exosome-derived microRNAs and proteins as potential biomarkers for distinguishing BD from MDD.
- Receiver Operating Characteristic analysis determined optimal concentration ranges for candidate biomarkers.
- Validation stage will assess the consistency of biomarker-indicated diagnosis with DSM-5 criteria and explore correlations with clinical features.
Conclusions:
- Exosome-derived microRNAs and proteins demonstrate potential as stable, information-rich mediums for exploring mental disorders due to their ability to cross the blood-brain barrier.
- Early diagnosis of BD, facilitated by exosome-based biomarkers, can enable timely intervention strategies.
- Improved diagnostic accuracy for BD is expected to significantly reduce the overall disease burden.
Related Concept Videos
01:36Overview of Exosomes
2.7K
Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
2.7K
01:30Bipolar Disorder
67
Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.
67